GLP-2 T

GLP-2 T is a research-grade injectable formulation designed for the exploration of dual incretin pathway modulation, metabolic regulation, and body weight management in experimental models. This compound functions as a dual agonist at GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors, making it a valuable tool for advancing research strategies in obesity and glucose control.

Mechanism of Action

• GLP-2 T activates both GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion while simultaneously reducing glucagon output. This mechanism supports research into improved glycemic control and the preservation of beta-cell function.
• Experimental studies indicate that this dual action is associated with significant improvements in insulin sensitivity and better management of fasting and postprandial glucose levels in models of metabolic disease.

Applications in Body Composition and Appetite Regulation

• Research on GLP-2 T has demonstrated its potential to induce reductions in body weight through mechanisms such as decreased appetite and lower caloric intake, with a possible bias towards fat mass loss over lean mass in obesity models.
• Investigations also focus on the compound’s effects on delayed gastric emptying and central satiety signaling, contributing to studies on long-term adherence and compensatory hunger mechanisms in weight-loss interventions.

Cardiometabolic Effects

• GLP-2 T is being studied for its favorable impacts on cardiovascular risk markers, including body weight and glycemic control, with potential implications for blood pressure and lipid profiles.
• Ongoing research is exploring its protective roles in reducing liver fat and improving kidney parameters, aligning GLP-2 T with broader contexts of metabolic syndrome and non-alcoholic fatty liver disease (NAFLD).

For research and laboratory use only. Not for human consumption.